:TDIQ

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 451219595

| IUPAC_name = 5,6,7,8-Tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline

| image = TDIQ.svg

| width =

| tradename =

| pregnancy_AU =

| pregnancy_US =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 15052-05-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = N2NE2TM9ZF

| PubChem = 27013

| ChemSpiderID = 25154

| synonyms = 6,7-Methylenedioxy-1,2,3,4-tetrahydroisoquinoline; 6,7-Methylenedioxy-THIQ; MDTHIQ; MDA-CR; "MDA-Conformationally Restricted"; MDA-THIQ; MDA/THIQ

| C=10 | H=11 | N=1 | O=2

| SMILES = c23OCOc2cc1CCNCc1c3

| StdInChI = 1S/C10H11NO2/c1-2-11-5-8-4-10-9(3-7(1)8)12-6-13-10/h3-4,11H,1-2,5-6H2

| StdInChIKey = JHLDJOBIUVJSTG-UHFFFAOYSA-N

}}

TDIQ, also known as MDTHIQ or MDA-CR, is a tetrahydroisoquinoline drug used in scientific research, which has anxiolytic and anorectic effects in animals.{{cite journal |vauthors=Young R, Rothman RB, Rangisetty JB, Partilla JS, Dukat M, Glennon RA |title=TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) inhibits the consumption of "snacks" in mice |journal=Pharmacology Biochemistry and Behavior |volume=84 |issue=1 |pages=74–83 |date=May 2006 |pmid=16750261 |doi=10.1016/j.pbb.2006.04.007 |s2cid=22564648 }}{{cite journal |vauthors=Young R, Batkai S, Dukat M, Glennon RA |title=TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice |journal=Pharmacology Biochemistry and Behavior |volume=84 |issue=1 |pages=62–73 |date=May 2006 |pmid=16750844 |doi=10.1016/j.pbb.2006.04.006 |s2cid=12307882 }} It has an unusual effects profile in animals, with the effects generalising to cocaine and partially to MDMA and ephedrine,{{cite journal |vauthors=Young R, Glennon RA |title=The stimulus effect of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline is similar to that of cocaine but different from that of amphetamine |journal=Pharmacology Biochemistry and Behavior |volume=71 |issue=1–2 |pages=205–13 |year=2002 |pmid=11812524 |doi= 10.1016/S0091-3057(01)00666-9|citeseerx=10.1.1.670.8659 |s2cid=16553365 }} but the effects did not generalise to amphetamine and TDIQ does not have any stimulant effects.{{cite journal |vauthors=Glennon RA, Young R, Rangisetty JB |title=Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline |journal=Pharmacology Biochemistry and Behavior |volume=72 |issue=1–2 |pages=379–87 |date=May 2002 |pmid=11900809 |doi= 10.1016/S0091-3057(01)00768-7|s2cid=33311107 }} It is thought these effects are mediated via a partial agonist action at Alpha-2 adrenergic receptors, and TDIQ has been suggested as a possible drug for the treatment of cocaine dependence.{{cite journal |author=Young R |title=TDIQ (5,6,7,8-tetrahydro-1,3-dioxolo [4,5-g]isoquinoline): discovery, pharmacological effects, and therapeutic potential |journal=CNS Drug Reviews |volume=13 |issue=4 |pages=405–22 |year=2007 |pmid=18078426 |doi=10.1111/j.1527-3458.2007.00022.x |pmc=6494129 }}